期刊文献+

肺动脉高压的治疗选择及其研究方向 被引量:2

下载PDF
导出
摘要 肺动脉高压( pulmonary arterial hypertension , PAH)属于肺循环高压( pulmonary hypertension )的一个亚群,是由不同原因导致、以肺动脉压力及阻力升高为特点的一组临床病理生理综合征,可导致右心负荷增加,最终右心衰竭而死亡。以往对于PAH的诊断标准是:在海平面状态下、静息时,右心导管检查肺动脉收缩压>30 mm Hg (1 mm Hg≈0.13 kPa)和(或)肺动脉平均压>25 mm Hg,或者运动时肺动脉平均压>30 mm Hg ,同时肺毛细血管楔压(PCWP)≤15 mm Hg[1]。但由于年龄等个体因素对于运动后肺动脉压力有显著的影响,因此在第4次WHO会议上取消了运动后PAH的诊断标准。
作者 张绍明
机构地区 解放军第
出处 《心血管外科杂志(电子版)》 2014年第2期80-82,共3页 Journal of Cardiovascular Surgery(Electronic Edition)
关键词 高血压 肺性 治疗
  • 相关文献

参考文献26

  • 1Barst RJ,McGoon M,Torbicki A. Diagnosis and differential assessment of pulmonary arterial hypertension[J].Journal of the America College of Cardiology,2004.40S-47S.
  • 2Sitbon O,Humbert M,Ja?s X. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension[J].CIRCULATION,2005.3105-3111.
  • 3罗显元,周学中,张维君.肺动脉高压的诊断和治疗进展[J].中华胸心血管外科杂志,2007,23(1):63-65. 被引量:13
  • 4Rubin LJ. Diagnosis and management of pulmonary arterial hyper-tension:ACCP evidence-based clinical practice guidelines[J].CHEST,2004.4S-6S.
  • 5Badesch DB,Abman SH,Ahearn GS. Medical therapy for pulmonary arterial hypertension:ACCP evidence-based clinical practice guidelines[J].CHEST,2004.35S-62S.
  • 6荆志成,徐希奇,马传荣,王勇,吴艳,蒋鑫,潘磊,杨跃进.波生坦治疗肺动脉高压患者的初步结果[J].中华医学杂志,2008,88(30):2136-2139. 被引量:18
  • 7GalièN,Olschewski H,Oudiz RJ. Ambrisentan for the treat-ment of pulmonary arterial hypertension:results of the ambrisen-tan in pulmonary arterial hypertension,randomized,double-blind,placebo-controlled,multicenter,efficacy (ARIES)study 1 and 2[J].CIRCULATION,2008.3010-3019.
  • 8Casserly B,Klinger JR. Ambrisentan for the treatment of pulmona-ry arterial hypertension[J].Drug Des Devel Ther,2009.265-280.
  • 9Jing ZC,Jiang X,Wu BX. Vardenafil treatment for patients with pulmonary arterial hypertension:a multicentre,open-label study[J].HEART,2009.1531-1536.
  • 10Fan YF,Zhang R,Jiang X. The phosphodiesterase-5 inhibi-tor vardenafil reduces oxidative stress while reversing pulmonary arterial hypertension[J].Cardiovascular Research,2013.395-403.

二级参考文献46

  • 1荆志成.六分钟步行距离试验的临床应用[J].中华心血管病杂志,2006,34(4):381-384. 被引量:98
  • 2Barst RJ,Langleben D,Badesch D,菅鑫妍.使用选择性内皮素A受体拮抗剂sitaxsentan治疗肺动脉高压[J].中国处方药,2006,5(8):29-29. 被引量:38
  • 3Rubin LJ. Primary pulmonary hypertension. N Engl J Med, 1997, 336: 111-117.
  • 4D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary, hypertension: results from a national prospective registry. Ann Intern Med, 1991, 115 : 343-349.
  • 5Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest, 2007, 132:373-379.
  • 6Badesch DB, Abman S H, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: up dated ACCP evidence-based clinical practice guidelines. Chest, 2007, 131:1917-1928.
  • 7McGoon M, Gutterman D, Steen V, et al. Screening, Early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest, 2004, 126: 14s-34s.
  • 8Gomez A, Bialostozky D, Zajarias A, et al. Right ventricular ischemia in patients with primary pulmonary hypertension. J Am Coll Cardiol, 2001, 38:1137-1142.
  • 9Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.N Engl J Med, 1993, 328:1732-1739.
  • 10Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med, 2004, 351:1655-1665.

共引文献30

同被引文献28

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部